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ABSTRACT
Clinical research is essential for the development of new drugs, diagnostic tests and new devices. Clinical monitoring is implemented 
to improve the quality of research and attain high ethical and scientific standards. This review discusses the role of clinical monitors, 
taking into account the variety of scenarios in which medical research is developed, and highlights the challenges faced by research 
teams to ensure that patients rights are respected and that the social role of scientific research is preserved. Specific emphasis is given 
to the ethical dilemmas related to the multiple roles which clinical monitors play in the research framework, mainly those involving the 
delicate equilibrium between the loyalty to the sponsor and to the research subjects. The essential role of clinical monitoring for research 
developed in poor healthcare scenarios is highlighted as an approach to get the local infrastructure strengthening needed to achieve an 
adequate level of good clinical practices. 
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INTRODUCTION
Clinical research is becoming an essential activity for the 
rational development of new pharmacological treatments, 
diagnostic tests and devices such as prostheses. The clinical 
research performed to substantiate the indication for new drugs, 
however, absorbs most of the efforts in this field1. The process for 
conducting research of adequate quality consumes a significant 
amount of the financial resources of the for-profit pharmaceutical 
industry, public agencies and, more recently, the non-profit, 
private organizations that assume the task of stimulating drug 
development for neglected diseases such as tuberculosis, sleeping 
sickness and leishmaniasis, among others2.
ReSeARCh SCeNARIOS
Regardless of the funding source for the development of 
clinical studies, the standardization of the appropriate conduct 
for studies is essential for trial success. Thus, the process has been 
established by the International Conference on Harmonisation 
through several recommendations that summarize the 
definitions, processes and functions of each professional 
involved in research. The goal of these recommendations is to 
standardize the criteria used in drug development to facilitate 
registration with the responsible agencies in the United States, 
Europe and Japan and to gather as much information as possible 
regarding experiments around the world3-6.
Certainly, there are different scenarios for clinical research 
that entail various levels of vulnerability for the different agents 
involved. Research volunteers have different socioeconomic 
conditions that directly impact their ability to consent to 
participate, and they are protected by legal frameworks that 
vary across countries and states. This vulnerability has been 
the subject of concern for more than five decades and the 
subject of discussion in the Declaration of Helsinki, a document 
that enshrines the basic principles of protection for study 
participants7-11.
The challenge of conducting biomedical research in a variety 
of scenarios is directly related to the need for universal ethical 
principles in a multicultural world that exhibits multiplicities 
of health care systems with significant differences in healthcare 
standards12-13.
The NeeD FOR ReSeARCh MONITORING
Clinical monitoring emerged from the need to monitor all 
processes related to study preparation, research implementation, 
research execution and procedures for the closure of field 
activities.
Concrete monitoring objectives include the following: 
protecting the rights and welfare of research participants; 
ensuring that the trial reports are complete and verifiable from 
source documents (previously agreed upon when planning 
the study); ensuring that the study is conducted according 
to the study protocol and the official modifications to the 
implementation process; and following good clinical practice 
and meeting all of the requirements of the applicable rules3. It is 
clear that monitors have two major dimensions to their activities: 
the ethical dimension related to protecting the research subjects 
and the technical dimension related to supervising specific 
activities during the research procedures. The need to ensure 
that these two dimensions are appropriately handled while 
developing studies imposes the need for monitoring. Thus, the 
monitor is an important agent in biomedical research.
MONITOR PROFILeS AND TheIR INTeGRATION  
IN ReSeARCh
Traditionally, it is recommended that the monitor be a 
professional who is properly qualified for the tasks of monitoring 
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and who possesses a thorough knowledge of good clinical 
practices to ensure an accurate adherence to research procedures 
and the implementation of appropriate corrective measures 
when there are deviations from the planned trial3. It is also 
essential that the monitor has a comprehensive knowledge of 
formal and informal ethical issues regarding the performance 
of biomedical research.
Thus, the first question regarding the role of the monitor 
involves their clinical integration and subordination to the 
other agents involved in the research including the project 
sponsor, the clinical investigator, the committee responsible 
for monitoring data on efficacy and safety14,15, the research 
ethics committee16,17 and the government regulatory agencies 
responsible for registering new drugs.
Regardless of the funding source for the research to be 
monitored, the monitor is usually appointed by the research 
sponsor to whom the monitor should be loyal. The principles that 
guide the monitor’s actions are within the general framework 
of good clinical practice. However, the extent and specific 
nature of the activities undertaken by the monitor are subject 
to the sponsor’s discretion. This discretionary monitoring is 
directly related to the assumption that different scenarios require 
different intensities and qualities of monitoring.
Considering the possibility that the monitor can act as a 
relentless watchdog of research activities and lose sight of the 
essential purpose of guaranteeing trial quality, it is beneficial 
to undergo a training process that promotes creative problem 
solving and enhances good clinical practices, including good 
laboratory practices, and the quality of the clinical laboratories 
that perform the research.
In addition, the monitor can be a professional who transforms 
situations that require improvements in the infrastructure and 
in reception and clinical care to make the situation suitable. 
This point is extremely relevant when considering the needs 
to develop drugs or diagnostic tests for neglected diseases 
because often the trial volunteers are treated at health facilities 
that are in poor condition. In this situation, the effort to achieve 
the appropriate standard of care to perform the studies should 
include the monitor’s active participation, especially during 
visits made before the trial begins.
From the moment the monitor is directly involved in the 
challenging task of helping to establish the conditions necessary 
for research and assumes the role of communicator and of the 
interpreter of local needs to the sponsor, there may be a shift, 
at least partially, of their loyalty from the sponsor toward a 
more basic and essential loyalty, the loyalty to the volunteers 
participating in the research, without which the monitor’s 
mission loses meaning.
The above aspects are important to avoid the risk of 
establishing a relationship based on mistrust between the 
sponsor and the investigator mediated by the monitor without 
losing monitor objectivity, thus contextualizing the relationships 
between sponsors, monitors and researchers in a sphere of 
confidence where the goals are the protection of participants 
and the excellence of scientific evidence to be obtained through 
research.
SPeCIFIC DUTIeS OF CLINICAL MONITORS
The description of the specific tasks in the process of 
monitoring clinical studies has been published in detail3. 
This review will emphasize, in addition to the main task of 
serving as the most important means of communication between 
the sponsor and the investigator, those tasks that directly ensure 
that the welfare and rights of research subjects are respected and 
that the quality of the data obtained is preserved.
It falls to the monitor to verify that the research team is 
qualified to perform the study and that its composition and 
training remain adequate throughout the research period. The 
monitor’s responsibility extends to tasks relating to the supply, 
supervision and disposal of the research materials, including 
the drug or the diagnostic test being studied and all relevant 
documentation for the investigator.
However, the monitor’s most important task is to ensure 
that the research is executed according to the protocol so that 
the rights and safety of subjects are guaranteed. Thus, the 
monitor’s participation is critical during an adverse reaction 
report to support the researchers according to the plan outlined 
in the protocol.
The monitor’s role as evaluator of the conditions surrounding 
the invitation of potential candidates to participate as research 
subjects, the conditions of the site for obtaining the informed 
consent form and the characteristics of the procedures for 
signing the consent form is also relevant and should be carefully 
reviewed during the monitor’s visit before starting the research. 
However, the most effort-consuming task is the review of the 
data collection forms for each subject to check the consistency 
of the information against the original documents that are used 
as original sources.
The activity of the monitors is usually summarized in 
reports submitted to the sponsor that include details of the 
activities performed during the monitoring visits, including 
the approaches adopted and those suggested to the researcher 
to correct or prevent potential problems.
The eThICAL ASSUMPTIONS OF MONITOR 
ACTIONS AND The ReLATIONShP TO The 
ReSeARCh eThICS COMMITTee
The following applies to the practice of clinical monitoring: 
all ethical principles that guide the activities of the researchers 
involved in the clinical studies; the Declaration of Helsinki; 
and all applicable international, national and institutional rules 
where research is performed. Although the clinical monitor 
does not have the direct responsibility of complying with the 
recommendations of all of these dispositions, it is up to the 
monitor to ensure that they are faithfully followed during the 
study. Therefore, the monitor becomes ethically and morally 
co-responsible for the actions taken. Although the sponsor and 
the investigator are legally responsible for the research and this 
responsibility appears to carry more relevant or larger direct 
implications, the monitor holds some moral responsibility. 
It is understood that the monitor’s role needs to be considered 
by the monitor and other agents involved in research.
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As the quality of the data obtained by the research depends 
directly and indirectly on the quality of monitoring, there is also 
the co-responsibility for what can happen when knowledge is 
disseminated.
Considering that currently, the use of any drug, diagnostic test or 
medical device depends on the quality of the scientific evidence that 
supports such use, the quality of monitoring will clearly be linked 
to the potential use that may be recommended from the results.
In the context of encouraging greater monitor participation 
from the early stages of implementing the studies, it is possible 
to consider the potential role of the monitor as a co-author of 
the articles to be published from the results of the monitored 
tests. By taking into account the concepts related to scientific 
authorship described by the International Committee of 
Medical Journal Editors18, it is suggested that the authors 
meet at least three conditions: first, a substantial contribution 
to the study’s concept and design, data collection, analysis or 
interpretation; second, drafting the article or critical revision of 
the article’s intellectual content; and third, approval of the final 
version to be published. Then, monitors do not strictly qualify 
as co-authors of a study. However, the crucial contribution of 
monitors to the development of studies should be recognized 
by name in the description of collaborations to prevent the 
monitor’s participation from remaining anonymous, thus 
reducing the risk of discouraging the professionalization of 
monitoring by means of public recognition in the academic 
environment.
The relationship between the monitor and the research 
ethics committee does not happen directly because the 
researcher and the sponsor assign the monitor. However, 
it falls to the monitor to quickly report any deviation or 
imminent risk to the research volunteers and to suggest that 
the investigator or sponsor inform the committee of any facts 
that are considered relevant. In this sense, the management 
of situations related mainly to the occurrence of serious 
adverse events is crucial, and the monitor must ensure that 
the information regarding these events can be transmitted to 
the sponsor as quickly as possible. The responsibility of the 
monitor for the group monitoring data on safety and efficacy 
is clearly indirect, and it is up to the sponsor to guarantee the 
flow of information that feeds group discussions and guides 
decision-making, especially when the early termination of a 
clinical trial is considered14.
MODeLS FOR MONITORING, CeRTIFICATION  
AND PROFeSSIONALIZATION
There are several models for the implementation of clinical 
monitoring. The most common is the monitoring of research 
contracted by a sponsor, or a so-called Contract Research 
Organization (CRO), and the financial recognition agreements 
for each activity are individually agreed upon with each monitor. 
The requirements for certification as a clinical monitor also vary 
depending on the sponsor, but there are organizations dedicated 
to this process. These organizations fall within the category of 
paid clinical monitors and become a source of consultation for 
recruiting monitors by the sponsors. The Brazilian Society of 
Professionals in Clinical Research has developed activities to 
improve and disseminate knowledge on this field and maintains 
a certification program for clinical monitors. The Tropical 
Diseases, Special Programme for Research and Training (TDR) 
initiative for monitoring the clinical trials of drug development 
for neglected diseases has the peculiarity of working with the 
system for training monitors who already have an employment 
relationship with other institutions and perform clinical 
monitoring ad honorem when working on projects supported 
by TDR. The training of monitors by TDR has been performed 
by the program itself; however, recently, the demand for an 
independent certifier has increased for both the program and the 
monitors. The biggest challenge now is implementing clinical 
monitoring for publicly funded research projects that are not 
given resources to pay for professional monitoring and depend, 
therefore, on ad honorem monitoring from partnerships with 
other institutions such as TDR or on non-certified monitors. 
Certainly, the spread of good clinical practice between the 
critical mass of researchers can facilitate the monitoring capacity 
for this situation. It can be argued that clinical monitoring is a 
profession established within the framework of clinical research 
and that, regardless of the funding model, follows the general 
principles of action that have improved the quality of clinical 
trials to make them more reliable and safe.
POSSIBILITIeS FOR CONSTRUCTING NeW  
PRACTICe SCeNARIOS
The appropriation of concepts and practices of good clinical 
practice by clinical research teams has a collateral impact on 
other research groups that perform epidemiological research. 
Often, researchers who perform clinical trials also perform 
epidemiological studies to identify risk factors for diseases. 
Therefore, the principles of good practice are easily transferred 
to the practice of epidemiological research, which also involves 
ethical dimensions and techniques that should be monitored 
to ensure the safety and welfare of research subjects and the 
quality of specific procedures. Healthcare in programs for the 
supervised treatment of diseases such as tuberculosis have 
shown that the monitoring tasks have flexibility and a potential 
for the appropriation of practices and specific responsibilities 
for each scenario where the diseases occur19. Likewise, the 
monitoring tasks could be performed by different agents 
depending on the type of study, the vulnerability and the local 
capacity for appropriating the concepts and practices that are 
relevant for high quality monitoring.
In conclusion, clinical monitoring is currently an essential 
activity to ensure the safety and welfare of research subjects 
and simultaneously improves the reliability of the data obtained 
and has an enormous potential for application, representing 
a constant challenge for its balanced implementation in the 
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